

GI Cancer Institute (NZ) Limited

Performance Report

For the year ended
31 March 2017


Contents

	Page
Non-Financial Information:	
Entity Information	2
Statement of Service Performance	5
Financial Information:	
Statement of Financial Performance	7
Statement of Financial Position	8
Statement of Cash Flows	9
Statement of Accounting Policies	10
Notes to the Performance Report	12
Independent Auditor's Report	19

The Board of Directors present the annual performance report of GI Cancer Institute (NZ) Limited for the year ended 31 March 2017, authorised for issue on 22nd September 2017.

For and on behalf of the Board of Directors

Director



Director

GI Cancer Institute (NZ) Limited

Entity Information

"Who are we?", "Why do we exist?"

For the year ended
31 March 2017

Legal Name of Entity:*	GI Cancer Institute (NZ) Limited
Other Name of Entity (if any):	GICI NZ, Gastro Intestinal Cancer Institute (NZ)
Type of Entity and Legal Basis (if any):*	Registered Company and Charitable Entity
Registration Number:	Charity number: CC 39174; Company number: 2195380

Entity's Purpose or Mission: *

The GI Cancer Institute of New Zealand (GICI) is dedicated to improving the outcomes for patients with gastro-intestinal cancer. GICI aims to increase awareness of GI cancers and raise funds to support clinical research in New Zealand, focusing particularly on clinical trials.

Gastro-intestinal (GI) cancer is a broad term used to encompass cancers of the digestive system: the oesophagus, stomach, liver, gallbladder, bile ducts, pancreas and bowel. It is collectively the most common form of cancer in New Zealand. Each year nearly 5,000 New Zealanders are diagnosed with a GI cancer; half of these people will die within five years of diagnosis. Yet despite being the most prevalent form of cancer, it is under-represented in funding and awareness.

To improve the survival rates of GI cancer, we must provide funding for clinical research. Clinical trials are the final link in the chain of medical research that take discoveries made in the laboratory and advance them into treatments that can improve survival rates and the quality of life for patients. By participating in clinical trials, patients gain the benefits of early access to leading-edge treatments, and their specialists have the opportunity to provide research-driven cancer care – which is care of the highest quality.

New Zealand patients and their specialists have had limited access to the many clinical trials that have shaped GI cancer treatment globally. The available funds for these ground-breaking clinical studies are insufficient and without better financial support, New Zealanders will miss out on the progress that is ongoing. GICI seeks to fill this funding gap to ensure that patients in New Zealand have access to the best possible treatments.

Entity Structure: *

GICI has a board of directors who meet 3 to 4 times a year. The board has a consumer representative, a marketing person and medical researchers in oncology and gastro intestinal cancers.

GICI was founded in 2009 by Professor Michael Findlay, bowel cancer survivor Grant Baker and pancreatic cancer survivor Paul Hargreaves. They, along with other esteemed medical experts and not-for-profit specialists, were inspired by Australia's GI Cancer Institute, a similar not-for-profit that raises money for the Australasian Gastro-Intestinal Trials Group (The AGITG). They were encouraged to establish a similar entity in New Zealand to fill the serious funding gap for clinical research. In addition to sharing the common goal of improving outcomes for GI cancer, GICI shares common Board members with the AGITG and maintains a close relationship with this very successful organisation. There is a Scientific Advisory Committee who meet once or twice a year through teleconferencing. They advise the board on clinical research and are based around New Zealand. There is an Executive Officer who manages the strategic and operational direction of the organisation reporting to the board of directors.

GI Cancer Institute (NZ) Limited

Entity Information

"Who are we?", "Why do we exist?"

**For the year ended
31 March 2017**

Main Sources of the Entity's Cash and Resources:*

Donations through events on behalf of GICI make up a significant income stream. Peer to peer fundraising through Everyday Hero has commenced. Every 1-2 years there is an annual major event called the GastroFest which raises significant funds for the organisation. Small amounts of funds for sponsorship and grants have been received. 2015 to 2016 strategic direction has an increase in awareness to enable an increase in donations and bequests in the future. Grant applications will be targeted through increased partnership with funding bodies. We receive no government funding. A small amount of funds are raised through a bank investment account.

Main Methods Used by the Entity to Raise Funds:*

Events on behalf of GICI such as Dine In for GICI programme.

Donations from high income individuals occur occasionally but can be significant.

One of the main fundraising events, GastroFest, was held in this financial year. Grant income was targeted more in this financial year.

Peer to peer fundraising will be targeted through a new fundraising platform. Dine In for GICI has commenced with two successful events in this financial year. Direct mail outs for donations have commenced with some success. Donations can be significant amounts however they fluctuate year to year.

Entity's Reliance on Volunteers and Donated Goods or Services: *

There is significant reliance on the goodwill of the board members who have major connections with business and wealthy individuals. The board is extremely supportive. Key board members are also able to liaise with services such as legal, accounting and auditing to ensure pro bono services are achieved. We hope to increase our volunteer base this year to create a 'Friends of GICI'.

GI Cancer Institute (NZ) Limited



Entity Information

"Who are we?"; "Why do we exist?"

**For the year ended
31 March 2017**

Additional Information:*

Contact details

Physical Address: Level 8, 85 Fort St, Auckland City, Auckland 1010	
Postal Address: PO Box 28723, Remuera, Auckland 1541	
Phone/Fax: 0800 112 775	
Email/Website: info@gicin.z.org.nz www.gicin.z.org.nz	
 https://www.facebook.com/gicin.z	
 https://twitter.com/GI_CancerNZ	

GI Cancer Institute (NZ) Limited
Statement of Service Performance
"What did we do?", When did we do it?"
For the year ended
31 March 2017

Description of the Entity's Outcomes*:

Awareness and Education campaign to raise the profile of GI cancers in New Zealand. Support clinical research and clinical research trials in New Zealand to improve the survival rates and quality of life for people with GI cancers living in New Zealand. Raise Awareness of GI and GI cancers through promotion, social media networking, written resources and distribution and community engagement.

Description and Quantification (to the extent practicable) of the Entity's Outputs:*	Actual*	Budget	Actual*
	This Year	This Year	Last Year
<p>Awareness Campaign for 2016 continued into April with the majority of the invoices being paid in this month. Radio and television</p> <ul style="list-style-type: none"> • Media release through local news with North Harbour Times and Stuff.co.nz picking up a personal story • World TV interview (Chinese TV in NZ) • Radio Live interview • Radio advertising for one month accessing 1,500 radio spots <p>Increased traffic through social media</p> <ul style="list-style-type: none"> • Facebook advertising with a reach to 128,056 people and engagement with 20,787 people • Use of a free Native Media Campaign through NZME accessed 2,000 people • Engagement of a Social Media Blogger 	\$26,427	\$21,500	\$14,875
<p>Ongoing awareness with monthly social media advertising continued with regular facebook promotion. Printing and stationary to promote the programmes occurred.</p> <p>Two clinical research projects commenced with \$40,949 funded. A Total of 5 clinical research trials are in progress with \$9,130 paid to providers. See additional information below.</p>	\$50,080	\$50,000	\$0
<p>Education sessions and Meet the Experts. One Meet the Experts with 20 people attending. 2nd Meet the Experts was cancelled as the Kaikoura earthquake occurred that week and the venue was unusable. Attempted a new date, however without another media budget we were unable to get enough people. Retirement homes for residents: 8 sessions for 154 people. Service Clubs: 7 clubs with 654 attending.</p>	\$6,731	\$10,000	\$2,000
<p>LoveYerGuts Awareness Campaign commenced planning and implementation on the 1st March 2017. LoveYerGuts is a peer to peer fundraising and awareness campaign based on people doing 50 gut crunches in 5 minutes on March 5th. A website and fundraising platform were created through the engagement of a strategic and marketing company who also provided pro bono support. Videos of people who had had a GI cancer were created to support engagement.</p>	\$6,074	6000	0

Additional Output Measures:

Additional Information:

In 2016 a Clinical Research Fellowship, funded annually by The Hugh Green Foundation, to the value of \$50,000 was established to support the clinical research workforce. The first round of applications did not result in a suitable applicant. GICI had also put out to the wider health community a funding round of \$50,000 for clinical research. Two suitable applicants resulted and after discussion with The Hugh Green Foundation, the fellowship was given out as a clinical research project. Two University of Otago clinical researchers were appointed, one study of immune responses to colorectal cancers to assist with appropriate use of chemotherapy and the other to study gut biome in relation to different colorectal cancers to determine differences in gut biome make-up. The gut biome study has potential to impact on prevention, detection and management. The immune response study develops further international studies to greater detail with potential for extremely important outcomes. A total of \$40,949 has been spent to date of the \$99,626 allocated to these two studies. Hugh Green Foundation have committed to providing a further \$100,000.

Clinical research trials funded this year included TopGear and A LaCART. SCOT had no further claims. Both A LaCART and SCOT trials have closed. Outcomes of A LaCART have been provided with the decision to continue with open surgery versus laparoscopic surgery for rectal cancers as the margins were not large enough from the cancer areas. SCOT trial outcomes have been reported at ASCO, an international conference, and to date it appears that 3 months of chemotherapy versus 6 months is adequate for survival rates at 3 years following diagnosis thus reducing the incidence of nerve damage due to chemotherapy and saving health funding. Funding for the Pancreatic Cancer DNA marker clinical trial had 10 patients allocated. However the ADHB have enrolled just 3 patients which they have yet to claim. Integrate 11 clinical trial was allocated \$8,850 for 3 patients to determine the effectiveness of a new chemotherapy on improved progressions free survival rates for oesophageal cancers. A total of \$9,130 has been spent on clinical trials this financial year. Tagged funding for clinical research trials \$19,350.

GI Cancer Institute (NZ) Limited
Statement of Financial Performance
 "How was it funded?" and "What did it cost?"
 For the year ended
 31 March 2017

	Note	Actual* This Year \$	Actual* Last Year \$
Revenue	1		
Fundraising and event income		156,645	129,253
Grant income and donations		163,049	85,469
Interest, dividends and other investment revenue*		1,481	3,884
Other revenue		31	
Total Revenue*		321,206	218,606
Expenses	2		
Expenses related to public fundraising*		106,777	42,516
Volunteer and employee related costs*	7	83,037	81,278
Grants and donations made*		50,080	-
Other expenses		11,075	3,282
Depreciation and amortisation		1,229	2,458
			-
Total Expenses*		252,198	129,534
Surplus for the Year*		69,008	89,072

GI Cancer Institute (NZ) Limited
Statement of Financial Position
"What the entity owns?" and "What the entity owes?"
As at
31 March 2017

	Note	Actual* This Year \$	Actual* Last Year \$
Assets			
Current Assets			
Bank accounts and cash*	3	303,981	277,398
Debtors and prepayments*	3	8,733	10,837
Total Current Assets		312,714	288,235
Non-Current Assets			
Property, plant and equipment*	3, 4	79	157
Intangible assets	3, 4	1,150	2,300
Investments	3	50,000	-
Total Non-Current Assets		51,229	2,457
Total Assets*		363,943	290,692
Liabilities			
Current Liabilities			
Creditors and accrued expenses*	3	18,385	13,631
Employee costs payable	3	8,035	8,546
		-	-
Total Current Liabilities		26,420	22,177
Total Liabilities*		26,420	22,177
Total Assets less Total Liabilities (Net Assets)*		337,523	268,515
Accumulated Funds			
Capital contributed by owners or members*	5	-	-
Accumulated surpluses*	5	224,962	207,461
Reserves*	5,6	112,561	61,054
Total Accumulated Funds*		337,523	268,515

GI Cancer Institute (NZ) Limited

Statement of Cash Flows

"How the entity has received and used cash"

For the year ended

31 March 2017

	Actual* This Year \$	Actual* Last Year \$
Cash Flows from Operating Activities*		
Cash was received from:		
Donations, fundraising and other similar receipts*	319,706	213,746
Interest, dividends and other investment receipts*	1,499	3,884
Net GST	1,498	(12,765)
Cash was applied to:		
Payments to suppliers and employees*	196,040	112,207
Donations or grants paid*	50,080	-
Net Cash Flows from Operating Activities*	76,583	92,658
Net Cash Flows from Investing and Financing Activities*	(50,000)	-
Net Increase / (Decrease) in Cash*	26,583	92,658
Opening Cash*	277,398	184,740
Closing Cash*	303,981	277,398
This is represented by:		
Bank Accounts and Cash*	303,981	277,398

GI Cancer Institute (NZ) Limited

Statement of Accounting Policies

"How did we do our accounting?"

For the year ended
31 March 2017

Basis of Preparation*

GI Cancer Institute (NZ) Limited has elected to apply PBE SFR-A (NFP) Public Benefit Entity Simple Format Reporting - Accrual (Not-For-Profit) ("Tier 3 Standard") on the basis that it does not have public accountability and has total annual expenses of equal to or less than \$2,000,000. All transactions in the Performance Report are reported using the accrual basis of accounting.

The Performance Report is prepared under the assumption that the entity will continue to operate in the foreseeable future.

Goods and Services Tax (GST)

GI Cancer Institute (NZ) Limited is registered for GST. All amounts are recorded exclusive of GST, except for Debtors and Creditors which are stated inclusive of GST.

Income Tax

GI Cancer Institute (NZ) Limited is wholly exempt from New Zealand income tax having fully complied with all statutory conditions for these exemptions.

Bank Accounts and Cash

Bank accounts and cash in the Statement of Cash Flows comprise cash balances and bank balances (including short term deposits) with original maturities of 90 days or less.

Investments

Investments comprise units in the Perpetual Guardian Philanthropy Fund.

Tangible Assets & Depreciation

The following are the classes of tangible assets:

Furniture and office equipment

All tangible assets are initially recorded at cost with depreciation being deducted on all tangible assets, other than freehold land, on a diminishing value basis at a rate of 50%.

Intangible Assets & Amortisation

The following are the classes of tangible assets:

Website

All intangible assets are initially recorded at cost with amortisation being deducted on all intangible assets, on a diminishing value basis at a rate of 50%.

GI Cancer Institute (NZ) Limited
Statement of Accounting Policies
"How did we do our accounting?"
For the year ended
31 March 2017

Revenue

Fundraising and event income are recognised in the period in which the events are held by GICI or in the period in which the funds are received from the third party holding the event on behalf of GICI.

Revenue from donations and grants with "use or return" conditions attached is recorded initially as a liability until the condition has been met, at which point the revenue is then recorded.

Revenue from donations and grants where there is no "use or return" condition that requires GICI to both apply the funds for a specific purpose and to return the funds if not used for that purpose, is recorded as revenue when the cash or assets are received. When the revenue from donations and grants is provided for a specific purpose but without a use or return condition, the revenue is held in restricted reserves within Accumulated Funds until used to keep track of the unspent balance.

Interest income is recorded using the effective interest method.

Accumulated Funds

Accumulated surpluses are unrestricted funds which are available for use at the discretion of the Directors in furtherance of GICI's objectives which have not been designated for other purposes.

Discretionary reserves are unrestricted funds reserved by the Directors for a specific purpose and created by a transfer from accumulated surpluses.

Restricted reserves may only be used for a specific purpose set by an external party, for example the express wishes of a donor; a specific purpose agreed with a donor; or the terms of a fundraising appeal.

Grants Made

Grants made are recognised as a liability when the entity has a binding commitment to make the grant and an obligation to make a transfer.

Agreements to make on-going grants are disclosed as commitments only for items abnormal in relation to the entities activities or to understand the future cash requirements of the entity.

Volunteer Services

The directors provide their services on a voluntary basis with no payment made. The audit is provided on a pro-bono basis. The value of these services has not been recognised in this performance report.

Changes in Accounting Policies*

There have been no changes in accounting policies. All policies have been applied on basis of consistent with those used in previous years.

GI Cancer Institute (NZ) Limited
Notes to the Performance Report
For the year ended
31 March 2017

Note 1 : Analysis of Revenue

Revenue Item	Analysis	This Year \$	Last Year \$
Fundraising events, events on behalf of GICI	Raising it for HILZ	-	23,100
	Bayleys SUPERCAR	-	102,300
	Santa House	3,014	3,853
	Gastrofest	121,784	-
	Dine In for GICI	14,190	-
	Running for Rebecca	2,994	-
	Big Boys Toys	14,183	-
	Jan Robinson Runs	480	-
	Total		156,645

Revenue Item	Analysis	This Year \$	Last Year \$
Grants: Lotteries Discretionary for AGITG conference \$2,076; The Hugh Green Foundation \$10,000 for Awareness Campaign LoveYerGuts and \$50,000 for Clinical Research; \$10,701 from Lions and Rotary clubs for clinical research; \$2,000 for Pancreatic cancer research.	Grants for current operations	12,076	30,637
	Donation for research	62,701	54,832
	Donations / Koha	88,272	-
Total		163,049	85,469

Revenue Item	Analysis	This Year \$	Last Year \$
Fees, subscriptions and other revenue from members	Other	31	-
	Total		31

Revenue Item	Analysis	This Year \$	Last Year \$
Interest, dividends and other investment revenue	Interest BNZ accounts	1,481	3,884
	Interest Perpetual Guardian Foundation Investment		
Total		1,481	3,884

GI Cancer Institute (NZ) Limited

Notes to the Performance Report

For the year ended
31 March 2017

Note 2 : Analysis of Expenses

Expense Item	Analysis	This Year \$	Last Year \$
Expenses related to public fundraising	Advertising	20,199	11,005
	Communications	7,492	-
	Conference expenses	2,788	1,101
	Design fees	1,583	5,433
	Event expenses	49,977	24,204
	Fundraising Institute membership	464	773
	LoveYerGuts expenses	24,274	-
Total		106,777	42,516

Expense Item	Analysis	This Year \$	This Year \$
Volunteer and employee related costs	ACC levies	-	344
	Salaries and Wages	82,798	80,934
	Expenses Travel kms	239	-
Total		83,037	81,278

Expense Item	Analysis	This Year \$	Last Year \$
Costs related to providing goods or services eg Meet the Experts and Awareness Campaign		-	-
		-	-
		-	-
Total		-	-

Expense Item	Analysis	This Year \$	This Year \$
Grants and donations made	Clinical Research	40,950	-
	Clinical Trials	9,130	-
Total		50,080	-

Expense Item	Analysis	This Year \$	This Year \$
Other expenses	Bank charges	1,522	520
	Computer and IT	4,234	585
	General expenses	899	749
	Printing, stamps and stationery	1,264	838
	Telephone, tolls and internet	953	590
	Insurance	1,680	-
	Entertainment	523	-
Total		11,075	3,282

Expense Item	Analysis	This Year \$	This Year \$
Depreciation and amortisation	Depreciation and amortisation	1,229	2,458
Total		1,229	2,458

GI Cancer Institute (NZ) Limited
Notes to the Performance Report
For the year ended
31 March 2017

Note 3 : Analysis of Assets and Liabilities

Asset Item	Analysis	This Year \$	Last Year \$
Bank accounts and cash	Cheque account balance	303,981	277,398
	Total	303,981	277,398

Asset Item	Analysis	This Year \$	Last Year \$
Debtors and prepayments	Accounts receivable	-	-
	RWT	625	1,230
	GST Receivable	8,108	9,607
Total		8,733	10,837

Asset Item	Analysis	This Year \$	Last Year \$
Investments	Investments	50,000	-
Total		50,000	-

Asset Item	Analysis	This Year \$	Last Year \$
Other non-current assets	Intangible assets	1,150	2,300
	Property, plant and equipment	79	157
Total		1,229	2,457

Liability Item	Analysis	This Year \$	Last Year \$
Creditors and accrued expenses	Trade and other payables	18,385	13,631
	GST Payable	-	-
Total		18,385	13,631

Liability Item	Analysis	This Year \$	Last Year \$
Employee costs payable	Wages and salaries earned but not yet paid	8,035	8,546
Total		8,035	8,546

GI Cancer Institute (NZ) Limited

Notes to the Performance Report

For the year ended
31 March 2017

Note 4 : Property, Plant and Equipment & Intangibles

This Year					
Property, Plant & Equipment	Opening Carrying Amount*	Purchases	Sales/Disposals	Current Year Depreciation and Impairment*	Closing Carrying Amount*
Computers (including software)*	157			78	79
Total	157	-	-	78	79

Last Year					
Property, Plant & Equipment	Opening Carrying Amount*	Purchases	Sales/Disposals	Current Year Depreciation and Impairment*	Closing Carrying Amount*
Computers (including software)*	315			158	157
Total	315	-	-	158	157

This Year					
Intangible Assets	Opening Carrying Amount*	Purchases	Sales/Disposals	Current Year Depreciation and Impairment*	Closing Carrying Amount*
Website	2,300			1,150	1,150
Total	2,300	-	-	1,150	1,150

Last Year					
Intangible Assets	Opening Carrying Amount*	Purchases	Sales/Disposals	Current Year Depreciation and Impairment*	Closing Carrying Amount*
Computers (including software)*	4,600			2,300	2,300
Total	4,600	-	-	2,300	2,300

GI Cancer Institute (NZ) Limited
Notes to the Performance Report
For the year ended
31 March 2017

Note 5: Accumulated Funds

This Year					
Description*	Capital Contributed by Owners or Members*	Accumulated Surpluses or Deficits*	Restricted Reserves*	Discretionary Reserves*	Total*
Opening Balance	-	207,461	17,032	44,022	268,515
Surplus/(Deficit)*		69,008	-	-	69,008
Transfer from Accumulated Surpluses to Restricted or Discretionary Reserves*		(149,047)	64,000	85,047	-
Transfer of amounts used or released from Restricted or Discretionary Reserves to Accumulated Surpluses		97,540	(48,069)	(49,471)	-
Closing Balance	-	224,962	32,963	79,598	337,523

Last Year					
Description*	Capital Contributed by Owners or Members*	Accumulated Surpluses or Deficits*	Restricted Reserves*	Discretionary Reserves*	Total*
Opening Balance	-	145,421	-	34,022	179,443
Surplus/(Deficit)*		89,072			89,072
Transfer to Reserves*		(27,032)			(27,032)
Transfer from Reserves*			17,032	10,000	27,032
Closing Balance	-	207,461	17,032	44,022	268,515

Breakdown of Reserves		Actual*	Actual*
Name*	Nature and	This Year	Last Year
		\$	\$
Restricted reserves	Awareness and Education and clinical research	30,963	17,032
Discretionary reserves	Education and awareness campaign, clinical trials and research	81,598	44,022
Total		112,561	61,054

GI Cancer Institute (NZ) Limited

Notes to the Performance Report

For the year ended
31 March 2017

Note 6 : Commitments and Contingencies

Commitment*	Explanation and Timing*	At balance date	At balance date
		This Year*	Last Year*
		\$	\$
Commitments to clinical trials and clinical research*	GICI has committed to clinical trials and research. Funds will be paid once certain conditions, in particular patient recruitment, are met. The committed amounts are held in Discretionary Reserves and Restricted Reserves within Accumulated Funds.	81,598	44,022

Contingent Liabilities and Guarantees

There are no contingent liabilities or guarantees as at balance date (Last Year - nil)

GI Cancer Institute (NZ) Limited

Notes to the Performance Report

For the year ended
31 March 2017

Notes 7-9

Note 7: Other

Goods or Services Provided to the Entity in Kind*

Description*

The directors provide their services on a voluntary basis with no payment made. Accountancy services are provided on a voluntary basis by a member of the Trilogy International Limited finance team and the audit and legal services are provided on a pro-bono basis by PwC and Chapman Tripp respectively.

The value of these services has not been recognised in this performance report.

Note 8: Related Party Transactions*

Description of Related Party Relationship*	Description of the Transaction (whether in cash or amount in kind)*	This Year	Last Year	This Year	Last Year
		\$	\$	\$	\$
		Value of Transactions*	Value of Transactions*	Amount Outstanding*	Amount Outstanding*
Reimbursement of cost to director (Grant Baker)	Cash reimbursement of costs incurred	-	6,139	-	6,139

Note 9: Events After the Balance Date*

This Year

Nature of Event*	Estimate of Financial Effect*	Effect, if any on the entity's ability to continue operating*
------------------	-------------------------------	---

No events have occurred since the balance date that would have a material impact on the Performance Report.



Independent auditor's report

To the Directors of GI Cancer Institute (New Zealand) Limited

Our audit of the performance report includes:

- the statement of financial position as at 31 March 2017;
- the statement of financial performance for the year then ended;
- the statement of cash flows for the year then ended;
- the statement of accounting policies for the year then ended; and
- the notes to the performance report.

Our audit engagement did not extend to include the statement of service performance or the entity information that are also included in GI Cancer Institute (New Zealand) Limited's performance report.

Our qualified opinion

In our opinion, except for the effect of any adjustments that might have been necessary had we been able to obtain sufficient evidence concerning donations as described in the Basis for qualified opinion section of our report, the performance report of GI Cancer Institute (New Zealand) Limited (the Company) on pages 7 to 18 presents fairly, in all material respects, the financial position of the Company as at 31 March 2017, and its financial performance and cash flows for the year ended on that date in accordance with Public Benefit Entity Simple Format Reporting – Accrual(Not-For-Profit).

Basis for qualified opinion

We conducted our audit of the statement of financial performance, the statement of financial position, the statement of cash flows, the statement of accounting policies and the related notes to the performance report that include other explanatory information in accordance with International Standards on Auditing (New Zealand) (ISAs NZ). Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the performance report* section of our report.

In common with other organisations of a similar nature, control over the revenues from donations prior to being banked is limited. It was not practicable to extend our examination of donations beyond the accounting for amounts received as shown in the accounting records of the Company, or to determine the effect of the limited control.


We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

We are independent of the Company in accordance with Professional and Ethical Standard 1 (Revised) *Code of Ethics for Assurance Practitioners* (PES 1) issued by the New Zealand Auditing and Assurance Standards Board and the International Ethics Standards Board for Accountants' *Code of Ethics for Professional Accountants* (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with these requirements.

Other than in our capacity as auditor we have no relationship with, or interests in, the Company.

Information other than the financial statements and auditor's report

The Directors are responsible for the performance report. Our opinion on the performance report does not include the entity information or the statement of service performance included in the performance report on pages 2 to 6 and we do not express any form of assurance conclusion on the entity information or statement of service performance.



In connection with our audit of the performance report, our responsibility is to read the entity information and statement of service performance and, in doing so, consider whether they are materially inconsistent with the performance report or our knowledge obtained during the audit, or otherwise appear to be materially misstated. If, based on the work we have performed on the entity information and the statement of service performance that we obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of the entity information and statement of service performance, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Directors for the performance report

The Directors are responsible, on behalf of the Company, for the preparation and fair presentation of the performance report in accordance with Public Benefit Entity Simple Format Reporting – Accrual (Not-For-Profit), and for such internal control as the Directors determine is necessary to enable the preparation of the performance report that is free from material misstatement, whether due to fraud or error.

In preparing the performance report, the Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the performance report

Our objectives are to obtain reasonable assurance about whether the performance report, as a whole, are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs NZ will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these performance report.

A further description of our responsibilities for the audit of the performance report is located at the External Reporting Board's website at:

https://xrb.govt.nz/Site/Auditing_Assurance_Standards/Current_Standards/Page8.aspx

This description forms part of our auditor's report.

Who we report to

This report is made solely to the Directors, as a body. Our audit work has been undertaken so that we might state those matters which we are required to state in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Directors, as a body, for our audit work, for this report or for the opinions we have formed.

The engagement partner on the audit resulting in this independent auditor's report is Indumin Senaratne.

For and on behalf of:

Chartered Accountants
22 September 2017

Auckland